Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Learn more about:
Related Clinical Trial
A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.
Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Repeated Controlled Human Schistosoma Mansoni Infection
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France
Monitoring Schistosome Hybrids Under Under Praziquantel Pressure
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
S. Japonicum and Pregnancy Outcomes
Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana
Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions
L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
Praziquantel in Children Under Age 4
Schistosoma Haematobium Infections and Praziquantel
Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis
Single-sex Female Controlled Human Schistosomiasis Mansoni Infection
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
Praziquantel-Pharmacokinetic Study
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults
Schistosomiasis in Senegal
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment
Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
Arachidonic Acid Treatment Against Schistosomiasis Infection in Children
Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
Health Benefits of Repeated Treatment in Pediatric Schistosomiasis
Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso